Log in

TG Therapeutics Stock Forecast, Price & News

+0.48 (+1.85 %)
(As of 10/29/2020 12:00 AM ET)
Today's Range
Now: $26.39
50-Day Range
MA: $27.12
52-Week Range
Now: $26.39
Volume918,674 shs
Average Volume2.00 million shs
Market Capitalization$3.34 billion
P/E RatioN/A
Dividend YieldN/A
TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and multiple sclerosis (MS). The company develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. It also develops Ublituximab, a novel anti-CD20 monoclonal antibody, which is in Phase III pivotal study for the treatment of CLL and MS; Umbralisib, a dual PI3K delta and CK1 epsilon inhibitor, which is in Phase III pivotal study for the treatment of CLL, and Phase 2b pivotal study for the treatment of marginal zone lymphoma and follicular lymphoma. In addition, the company develops TG-1501, an anti-PD-L1 monoclonal antibody, which is in Phase I pivotal study for the treatment of B-cell cancers; TG-1701, an oral Bruton's Tyrosine Kinase, which is in Phase I pivotal study for the treatment of B-cell cancers; and TG-1801, an anti-CD47/CD19 bispecific antibody that is in Phase I pivotal study for the treatment of B-cell cancers. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Read More
TG Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TGTX



Sales & Book Value

Annual Sales$150,000.00
Price / Sales22,281.78
Book Value$0.39 per share


Net Income$-172,870,000.00
Net Margins-135,198.03%


Market Cap$3.34 billion
Next Earnings Date11/10/2020 (Estimated)
+0.48 (+1.85 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

How has TG Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX shares have increased by 163.6% and is now trading at $26.39.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of TG Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TG Therapeutics

When is TG Therapeutics' next earnings date?

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for TG Therapeutics

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) released its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.15. The biopharmaceutical company earned $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative net margin of 135,198.03% and a negative return on equity of 384.84%.
View TG Therapeutics' earnings history

What price target have analysts set for TGTX?

5 brokers have issued 12-month target prices for TG Therapeutics' stock. Their forecasts range from $37.00 to $60.00. On average, they anticipate TG Therapeutics' stock price to reach $44.20 in the next year. This suggests a possible upside of 67.5% from the stock's current price.
View analysts' price targets for TG Therapeutics

Who are some of TG Therapeutics' key competitors?

What other stocks do shareholders of TG Therapeutics own?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the following people:
  • Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 54, Pay $827.54k)
  • Mr. Sean A. Power CPA, CPA, CFO, Corp. Sec. & Treasurer (Age 38, Pay $470.56k)
  • Dr. Owen A. O'Connor, Chief Scientific Officer
  • Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
  • Mr. Adam Waldman, Chief Commercial Officer

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Candriam Luxembourg S.C.A. (1.19%), State of New Jersey Common Pension Fund D (0.07%), Edge Wealth Management LLC (0.03%), Nisa Investment Advisors LLC (0.02%), Cambridge Investment Research Advisors Inc. (0.01%) and SlateStone Wealth LLC (0.01%). Company insiders that own TG Therapeutics stock include Michael S Weiss, Ra Capital Management, LP, Sean A Power and William James Kennedy.
View institutional ownership trends for TG Therapeutics

Which major investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., State of New Jersey Common Pension Fund D, Exane Derivatives, and DAVENPORT & Co LLC. Company insiders that have sold TG Therapeutics company stock in the last year include Ra Capital Management, LP, and William James Kennedy.
View insider buying and selling activity for TG Therapeutics

Which major investors are buying TG Therapeutics stock?

TGTX stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc., Stoneridge Investment Partners LLC, Pacer Advisors Inc., Nisa Investment Advisors LLC, SlateStone Wealth LLC, and Edge Wealth Management LLC.
View insider buying and selling activity for TG Therapeutics

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $26.39.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $3.34 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-172,870,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. TG Therapeutics employs 176 workers across the globe.

What is TG Therapeutics' official website?

The official website for TG Therapeutics is www.tgtherapeutics.com.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.